Efficacy of Autologous Bone Marrow–Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus

2009 ◽  
Vol 18 (10) ◽  
pp. 1407-1416 ◽  
Author(s):  
Anil Bhansali ◽  
Vimal Upreti ◽  
N. Khandelwal ◽  
N. Marwaha ◽  
Vivek Gupta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Autologous Bone

scholarly journals A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

2019 ◽  
Vol 6 (1) ◽  
pp. 2966-2969 ◽  
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Insulin Injection ◽  
Autologous Bone

Introduction: Type 2 diabetes mellitus (T2DM) iscurrently one of the most common diseases as a result of obesity and aging. Currently, T2DMis treated by various methods, such as insulin injection and glucose regulation agents. In this report, we report the case of a T2DM patient who was successfully treated by autologous bone marrow-derived stem cell transplantation. Methods: The patient was diagnosed with T2DM by standard methods for more than ten years. The patient agreed to be treated by the new approach – autologous bone marrow-derived stem cell transplantation. The bone marrow was collected from the patient twice at 100 mL volume each time. The stem cellenriched mononuclear cells (MNCs) in the bone marrow were isolated by gradient centrifugation. MNCs were intravenously transfused into the patient twice within the 1-month interval. The lasting glucose and 2h-after meal glucose, as well as hemoglobin A1c (Hab1c), were recorded before transplantation, and 1-, 3-, and 6-months post-transplantation. Results: The results showed that there were no adverse effect recorded during the monitoring period, and that the T2DM symptoms significantly improved. After the first round of transplantation, the glucose level reduced considerably and continued to decrease out to 3 months. Meanwhile, after 2 months of transplantation, the Hab1C level decreased and achieved the average level at the 3rd month of treatment. After 6 months, the patient was free from insulin injection and maintained glucose and Hab1c level. To date, after 9 months of treatment; the patients has continued to be free from insulin injection and without any adverse effects. Conclusion: The primary results have suggested that autologous bone marrow-derived stem cell transplantation may be a new direction for T2DM treatment.  

scholarly journals CORRECTION: A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

2019 ◽  
Vol 6 (4) ◽  
pp. 3140
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Autologous Bone Marrow ◽  
Diabetes Mellitus Patient ◽  
Autologous Bone

In the previous publication with title ”A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report”1, page 2968, in the Table 1, the unit for fasting blood glucose and blood glucose 2 hours after meals is mg/dL; however, the corrected unit for fasting blood glucose and blood glucose 2 hours after meal is mmol/L.  

scholarly journals Rationale for stem cell therapy for type 2 diabetes mellitus

2017 ◽  
Vol 4 (02) ◽  
pp. 1166
Author(s):  
Kumar Sushaniba
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Stem Cell Therapy

Stem cells can be differentiated into many types of mature cells. Among degenerative diseases, type 1 diabetes mellitus (T1DM) is considered to be a good target disease for stem cell therapeutic application. Indeed, several studies have suggested that stem cells can be differentiated, both in vitro and in vivo, into beta cells which regenerate the pancreas. However, recent studies have shown that stem cell therapy can also provide benefits for type 2 diabetes mellitus (T2DM), which is not related to beta cell degeneration in the pancreas. This commentary will discuss the opportunity to use mesenchymal stem cells (MSCs) to treat T2DM, citing various stem cell therapies from recent published studies. Indeed, a current report “Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus, Biomedical Research and Therapy, 3(12): 1034-1044” evaluated and confirmed the positive effects of stem cell transplantation for blood glucose regulation in T2DM.

Biodistribution of 18F-FDG-Labeled Autologous Bone Marrow–Derived Stem Cells in Patients With Type 2 Diabetes Mellitus

2015 ◽  
Vol 40 (9) ◽  
pp. 697-700 ◽  
Author(s):  
Vikas Sood ◽  
Bhagwant R. Mittal ◽  
Anil Bhansali ◽  
Baljinder Singh ◽  
Niranjan Khandelwal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Autologous Bone Marrow ◽  
Autologous Bone ◽  
18F Fdg
Sign in / Sign up

Export Citation Format

Share Document